Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739742 | 0.93 | CNR1 (0.48) | CNR1CNR2OPRM1PSMB8PSMB9 | |
| SCHEMBL29291165 | 0.86 | CNR1 (0.46) | CNR1CNR2AURKARPS6KB1RIPK1 | |
| SCHEMBL19634927 | 0.81 | FAAH (0.48) | CNR1CNR2 | |
| SCHEMBL1738181 | 0.79 | CNR1 (0.49) | CNR1CNR2PSMB8PSMB9CCR5 | |
| SCHEMBL2795047 | 0.79 | PSMB8 (0.44) | CNR1CNR2MAP3K14PSMB8PSMB9 | |
| SCHEMBL5449676 | 0.78 | PRCP (0.45) | PRCPCCR5 | |
| SCHEMBL1741743 | 0.76 | CNR1 (0.42) | CNR1CNR2PSMB8PSMB9PRCP | |
| SCHEMBL1741747 | 0.76 | CNR1 (0.42) | CNR1CNR2PSMB8PSMB9PRCP | |
| SCHEMBL12542569 | 0.75 | RET (0.44) | MAP3K14OPRM1PSMB8PSMB9L3MBTL1 | |
| SCHEMBL2799348 | 0.75 | PRCP (0.37) | CNR1CNR2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8492393-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-23 | — | — | US | disclosed |
| US-8486954-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8431584-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20130005750-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
| US-20130005750-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | CNR1 717/4885CNR2 557/4885MAP3K14 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.